The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Avandaryl     5-[[4-[2-(methyl-pyridin-2- yl...

Synonyms: Avandia, Gaudil, Rosiglizole, Rosi, rosiglitazona, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Rosiglitazone maleate


Psychiatry related information on Rosiglitazone maleate


High impact information on Rosiglitazone maleate


Chemical compound and disease context of Rosiglitazone maleate


Biological context of Rosiglitazone maleate


Anatomical context of Rosiglitazone maleate


Associations of Rosiglitazone maleate with other chemical compounds


Gene context of Rosiglitazone maleate


Analytical, diagnostic and therapeutic context of Rosiglitazone maleate

  • About half of those genes were upregulated after treatment with rosiglitazone, and this was accompanied by an increase in mitochondrial mass and changes in mitochondrial structure [17].
  • However, rosiglitazone decreased % liver fat (spectroscopy) and serum insulin concentrations, and normalized liver function tests [24].
  • We report here that oral administration of thiazolidinediones (rosiglitazone and troglitazone) remarkably inhibited insulin-like growth factor-I (IGF-I)-promoted skin tumor development by 73% in BK5.IGF-1 transgenic mice, although they were previously found to be ineffective in inhibiting UV- or chemically induced mouse skin tumorigenesis [43].
  • To determine the specific effects of rosiglitazone (RSG) on beta-cell mass dynamics, male fa/fa (obese) and +/fa or +/+ (lean) rats age 6 weeks were fed either chow (control group [CN]) or chow mixed with rosiglitazone (RSG group) at a dosage of 10 micromol. kg(-1) body [44].
  • The present study examines the effect of rosiglitazone treatment on cardiac insulin sensitization and its association with cardioprotection from ischemia/reperfusion injury in an animal model of diabetes [45].


  1. The hormone resistin links obesity to diabetes. Steppan, C.M., Bailey, S.T., Bhat, S., Brown, E.J., Banerjee, R.R., Wright, C.M., Patel, H.R., Ahima, R.S., Lazar, M.A. Nature (2001) [Pubmed]
  2. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. Fonseca, V., Rosenstock, J., Patwardhan, R., Salzman, A. JAMA (2000) [Pubmed]
  3. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. Stühlinger, M.C., Abbasi, F., Chu, J.W., Lamendola, C., McLaughlin, T.L., Cooke, J.P., Reaven, G.M., Tsao, P.S. JAMA (2002) [Pubmed]
  4. PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. Heaney, A.P., Fernando, M., Melmed, S. J. Clin. Invest. (2003) [Pubmed]
  5. A randomized, placebo-controlled trial of rosiglitazone for HIV-related lipoatrophy. Cavalcanti, R.B., Raboud, J., Shen, S., Kain, K.C., Cheung, A., Walmsley, S. J. Infect. Dis. (2007) [Pubmed]
  6. Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Mody, M., Dharker, N., Bloomston, M., Wang, P.S., Chou, F.S., Glickman, T.S., McCaffrey, T., Yang, Z., Pumfery, A., Lee, D., Ringel, M.D., Pinzone, J.J. Endocr. Relat. Cancer (2007) [Pubmed]
  7. Effects of rosiglitazone on the liver histology and mitochondrial function in ob/ob mice. García-Ruiz, I., Rodríguez-Juan, C., Díaz-Sanjuán, T., Martínez, M.A., Muñoz-Yagüe, T., Solís-Herruzo, J.A. Hepatology (2007) [Pubmed]
  8. Rosiglitazone treatment reduces diabetic neuropathy in streptozotocin-treated DBA/2J mice. Wiggin, T.D., Kretzler, M., Pennathur, S., Sullivan, K.A., Brosius, F.C., Feldman, E.L. Endocrinology (2008) [Pubmed]
  9. Rosiglitazone modulates the innate immune response to Plasmodium falciparum infection and improves outcome in experimental cerebral malaria. Serghides, L., Patel, S.N., Ayi, K., Lu, Z., Gowda, D.C., Liles, W.C., Kain, K.C. J. Infect. Dis. (2009) [Pubmed]
  10. Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Pedersen, W.A., McMillan, P.J., Kulstad, J.J., Leverenz, J.B., Craft, S., Haynatzki, G.R. Exp. Neurol. (2006) [Pubmed]
  11. The effect of rosiglitazone in the prevention of intra-abdominal adhesion formation in a rat uterine horn model. Demirturk, F., Aytan, H., Caliskan, A., Aytan, P., Yener, T., Koseoglu, D., Yenisehirli, A. Hum. Reprod. (2006) [Pubmed]
  12. Is weight loss possible in patients treated with thiazolidinediones? Experience with a low-calorie diet. Asnani, S., Richard, B.C., Desouza, C., Fonseca, V. Current medical research and opinion. (2003) [Pubmed]
  13. Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors. Lloyd, S., Hayden, M.J., Sakai, Y., Fackett, A., Silber, P.M., Hewitt, N.J., Li, A.P. Chem. Biol. Interact. (2002) [Pubmed]
  14. Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Heaney, A.P., Fernando, M., Yong, W.H., Melmed, S. Nat. Med. (2002) [Pubmed]
  15. Lysophosphatidic acid induces neointima formation through PPARgamma activation. Zhang, C., Baker, D.L., Yasuda, S., Makarova, N., Balazs, L., Johnson, L.R., Marathe, G.K., McIntyre, T.M., Xu, Y., Prestwich, G.D., Byun, H.S., Bittman, R., Tigyi, G. J. Exp. Med. (2004) [Pubmed]
  16. Search for the preadipocyte progenitor cell. Hausman, G.J., Hausman, D.B. J. Clin. Invest. (2006) [Pubmed]
  17. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. Wilson-Fritch, L., Nicoloro, S., Chouinard, M., Lazar, M.A., Chui, P.C., Leszyk, J., Straubhaar, J., Czech, M.P., Corvera, S. J. Clin. Invest. (2004) [Pubmed]
  18. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the zucker Fatty rat heart. Sidell, R.J., Cole, M.A., Draper, N.J., Desrois, M., Buckingham, R.E., Clarke, K. Diabetes (2002) [Pubmed]
  19. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats. Walker, A.B., Chattington, P.D., Buckingham, R.E., Williams, G. Diabetes (1999) [Pubmed]
  20. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation. Koh, E.H., Kim, M.S., Park, J.Y., Kim, H.S., Youn, J.Y., Park, H.S., Youn, J.H., Lee, K.U. Diabetes (2003) [Pubmed]
  21. Treatment of Spontaneously Hypertensive Rats With Rosiglitazone and/or Enalapril Restores Balance Between Vasodilator and Vasoconstrictor Actions of Insulin With Simultaneous Improvement in Hypertension and Insulin Resistance. Potenza, M.A., Marasciulo, F.L., Tarquinio, M., Quon, M.J., Montagnani, M. Diabetes (2006) [Pubmed]
  22. PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. Panigrahy, D., Singer, S., Shen, L.Q., Butterfield, C.E., Freedman, D.A., Chen, E.J., Moses, M.A., Kilroy, S., Duensing, S., Fletcher, C., Fletcher, J.A., Hlatky, L., Hahnfeldt, P., Folkman, J., Kaipainen, A. J. Clin. Invest. (2002) [Pubmed]
  23. Collecting duct-specific deletion of peroxisome proliferator-activated receptor gamma blocks thiazolidinedione-induced fluid retention. Zhang, H., Zhang, A., Kohan, D.E., Nelson, R.D., Gonzalez, F.J., Yang, T. Proc. Natl. Acad. Sci. U.S.A. (2005) [Pubmed]
  24. Rosiglitazone in the treatment of HAART-associated lipodystrophy--a randomized double-blind placebo-controlled study. Sutinen, J., Häkkinen, A.M., Westerbacka, J., Seppälä-Lindroos, A., Vehkavaara, S., Halavaara, J., Järvinen, A., Ristola, M., Yki-Järvinen, H. Antivir. Ther. (Lond.) (2003) [Pubmed]
  25. Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Wilson-Fritch, L., Burkart, A., Bell, G., Mendelson, K., Leszyk, J., Nicoloro, S., Czech, M., Corvera, S. Mol. Cell. Biol. (2003) [Pubmed]
  26. Hepatic failure in a patient taking rosiglitazone. Forman, L.M., Simmons, D.A., Diamond, R.H. Ann. Intern. Med. (2000) [Pubmed]
  27. PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Welch, J.S., Ricote, M., Akiyama, T.E., Gonzalez, F.J., Glass, C.K. Proc. Natl. Acad. Sci. U.S.A. (2003) [Pubmed]
  28. Inhibition of IkappaB kinase and IkappaB phosphorylation by 15-deoxy-Delta(12,14)-prostaglandin J(2) in activated murine macrophages. Castrillo, A., Díaz-Guerra, M.J., Hortelano, S., Martín-Sanz, P., Boscá, L. Mol. Cell. Biol. (2000) [Pubmed]
  29. Peroxisome proliferator-activated receptor gamma controls Muc1 transcription in trophoblasts. Shalom-Barak, T., Nicholas, J.M., Wang, Y., Zhang, X., Ong, E.S., Young, T.H., Gendler, S.J., Evans, R.M., Barak, Y. Mol. Cell. Biol. (2004) [Pubmed]
  30. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Schaefer, K.L., Wada, K., Takahashi, H., Matsuhashi, N., Ohnishi, S., Wolfe, M.M., Turner, J.R., Nakajima, A., Borkan, S.C., Saubermann, L.J. Cancer Res. (2005) [Pubmed]
  31. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Brunmair, B., Staniek, K., Gras, F., Scharf, N., Althaym, A., Clara, R., Roden, M., Gnaiger, E., Nohl, H., Waldhäusl, W., Fürnsinn, C. Diabetes (2004) [Pubmed]
  32. Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist/hip ratio. Mulligan, K., Yang, Y., Wininger, D.A., Koletar, S.L., Parker, R.A., Alston-Smith, B.L., Schouten, J.T., Fielding, R.A., Basar, M.T., Grinspoon, S. AIDS (2007) [Pubmed]
  33. Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women. Berberoglu, Z., Gursoy, A., Bayraktar, N., Yazici, A.C., Bascil Tutuncu, N., Guvener Demirag, N. J. Clin. Endocrinol. Metab. (2007) [Pubmed]
  34. Rosiglitazone prevents free fatty acid-induced vascular endothelial dysfunction. Mittermayer, F., Schaller, G., Pleiner, J., Krzyzanowska, K., Kapiotis, S., Roden, M., Wolzt, M. J. Clin. Endocrinol. Metab. (2007) [Pubmed]
  35. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. Li, A.C., Brown, K.K., Silvestre, M.J., Willson, T.M., Palinski, W., Glass, C.K. J. Clin. Invest. (2000) [Pubmed]
  36. Peroxisome proliferator-activated receptor-gamma down-regulates chondrocyte matrix metalloproteinase-1 via a novel composite element. François, M., Richette, P., Tsagris, L., Raymondjean, M., Fulchignoni-Lataud, M.C., Forest, C., Savouret, J.F., Corvol, M.T. J. Biol. Chem. (2004) [Pubmed]
  37. Peroxisome proliferator-activated receptor gamma inhibits the migration of dendritic cells: consequences for the immune response. Angeli, V., Hammad, H., Staels, B., Capron, M., Lambrecht, B.N., Trottein, F. J. Immunol. (2003) [Pubmed]
  38. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Patel, L., Pass, I., Coxon, P., Downes, C.P., Smith, S.A., Macphee, C.H. Curr. Biol. (2001) [Pubmed]
  39. Effects of metformin and rosiglitazone treatment on insulin signaling and glucose uptake in patients with newly diagnosed type 2 diabetes: a randomized controlled study. Karlsson, H.K., Hällsten, K., Björnholm, M., Tsuchida, H., Chibalin, A.V., Virtanen, K.A., Heinonen, O.J., Lönnqvist, F., Nuutila, P., Zierath, J.R. Diabetes (2005) [Pubmed]
  40. Regulation of adiponectin receptors in hepatocytes by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Sun, X., Han, R., Wang, Z., Chen, Y. Diabetologia (2006) [Pubmed]
  41. Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. Boyle, J.G., Logan, P.J., Ewart, M.A., Reihill, J.A., Ritchie, S.A., Connell, J.M., Cleland, S.J., Salt, I.P. J. Biol. Chem. (2008) [Pubmed]
  42. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reverses the adverse effects of diet-induced obesity on oocyte quality. Minge, C.E., Bennett, B.D., Norman, R.J., Robker, R.L. Endocrinology (2008) [Pubmed]
  43. Thiazolidinediones inhibit insulin-like growth factor-i-induced activation of p70S6 kinase and suppress insulin-like growth factor-I tumor-promoting activity. He, G., Sung, Y.M., Digiovanni, J., Fischer, S.M. Cancer Res. (2006) [Pubmed]
  44. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Finegood, D.T., McArthur, M.D., Kojwang, D., Thomas, M.J., Topp, B.G., Leonard, T., Buckingham, R.E. Diabetes (2001) [Pubmed]
  45. Rosiglitazone treatment in Zucker diabetic Fatty rats is associated with ameliorated cardiac insulin resistance and protection from ischemia/reperfusion-induced myocardial injury. Yue, T.L., Bao, W., Gu, J.L., Cui, J., Tao, L., Ma, X.L., Ohlstein, E.H., Jucker, B.M. Diabetes (2005) [Pubmed]
WikiGenes - Universities